Related Experiment Video
Updated: Aug 16, 2025
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
550
Yttrium-90 Radioembolization: Current Indications and Outcomes
Ahmad Hamad1, Hassan Aziz2, Ihab R Kamel3
1Department of Surgery, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, OH, USA.
Summary
90Yttrium (Y90) radioembolization (RE) is effective for advanced liver cancer (HCC) and increasingly shows promise for early and intermediate stages. This treatment offers comparable survival and response rates, expanding its role in HCC management.
Area of Science:
- Hepatobiliary Oncology
- Interventional Radiology
- Nuclear Medicine
Background:
- 90Yttrium (Y90) radioembolization (RE) traditionally treats advanced hepatocellular carcinoma (HCC).
- Emerging evidence supports RE's safety and feasibility in early and intermediate HCC stages.
- This review examines current data on Y90 RE for HCC across various disease stages.
Purpose of the Study:
- To review the evidence for 90Yttrium radioembolization in hepatocellular carcinoma.
- To assess the efficacy of Y90 RE in early, intermediate, and advanced HCC.
- To explore the expanding role of Y90 RE in HCC treatment paradigms.
Main Methods:
- Comprehensive literature review.
- Searched MEDLINE/PubMed and Web of Science databases.
- Search concluded August 1, 2022.
Main Results:
- Y90 RE demonstrates promising results in early (BCLC A), intermediate (BCLC B), and advanced (BCLC C) HCC.
- Outcomes (overall survival, progression-free survival, response rates) are comparable to standard treatments.
- Y90 RE serves as a downstaging option for advanced HCC outside liver transplant criteria.
- Radiation lobectomy (RL) is a technique using RE to treat HCC-bearing liver segments while promoting future liver remnant hypertrophy.
Conclusions:
- 90Yttrium radioembolization is evolving from a palliative treatment to a key component of multi-modality HCC care.
- Y90 RE is effective across a broad spectrum of HCC clinical indications.
- The role of Y90 RE in HCC management continues to expand.
